Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 37% Improvement Relative Risk ICU admission -1% Aspirin for COVID-19  Zadeh et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective study in the USA Lower mortality with aspirin (not stat. sig., p=0.28) c19early.org Zadeh et al., Innovation in Aging, Dec 2022 Favors aspirin Favors control

Effect of aspirin in COVID-19 outcomes of older adults with a history of coronary artery disease

Zadeh et al., Innovation in Aging, doi:10.1093/geroni/igac059.3047
Dec 2022  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 4,017 coronary artery disease patients hospitalized for COVID-19 in the USA, showing no significant difference in outcomes with low dose aspirin use.
risk of death, 37.0% lower, RR 0.63, p = 0.28.
risk of ICU admission, 1.0% higher, RR 1.01, p = 0.79.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zadeh et al., 20 Dec 2022, retrospective, USA, peer-reviewed, mean age 62.2, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
IMPACT OF OACS ON OUTCOMES OF COVID-19 INFECTION IN OLDER ADULTS WITH HISTORY OF ATRIAL FIBRILLATION
Ricardo Criado Carrero, Andrew Carl Crawford, Ali Vaeli Zadeh, Alan Wong, Ana De, Diego Diaz, Elias Collado, Joshua Larned, Amy Ai, Crim Sabuncu, Ali Vaeli Zadeh, Ricardo Criado Carrero, Noah Mandile, Marina Stukova, German Lopez, Holy Cross
diseases. Records from both groups were reviewed for the first episode of HF over 12 months following the initiation of treatment. Pearson's chi-squared test was used to compare groups. The strength of association was reported using Risk Ratios (RR). A p-value < 0.05 was deemed significant. Results: 6,446 were included in each group. The mean age, gender and ECI were indifferent. 958 (15%) of patients treated with AADs and 987 (15.3%) of patients treated with CA had a first episode of HF over a year after the treatment which was not significantly different between groups (RR=1.03, CI95% = 0.95-1.11, p=0.49). Conclusion: The modality of treatment after the first episode of AF in older population doesn't significantly affect the risk of HF over the first year.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit